All In Biotech

Drug Trial Radar · NCT07359820

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Sep 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Elevar TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.

Conditions

  • FGFR2 Gene Fusion/Rearrangement
  • Other Solid Tumors, Adult

Interventions

  • LirafugratinibDrug

    Lirafugratinib is an oral inhibitor of FGFR2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) assessed by Independent Review Committee per RECIST v1.1.Time frame: Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months.

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Not yet recruiting

  • Mayo Clinic

    Jacksonville, Florida · Not yet recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Institut Bergonie

    Bordeaux, France · Not yet recruiting

  • Centre Georges François Leclerc

    Dijon, France · Not yet recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Gustave Roussy Cancer Campus

    Paris, France · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • START Barcelona-Hospital HM Nou Delfos

    Barcelona, Spain · Recruiting

  • Hospital Universitario Fundación Jiménez Díaz- START MADRID

    Madrid, Spain · Recruiting

  • Hospital Universitario HM Sanchinarro-START MADRID-CIOCC

    Madrid, Spain · Recruiting

  • Sarah Cannon Research Institute UK

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.